Annual report for Granules India Ltd. for FY-2018
24-05-2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Earnings Conference call for Q4, FY2017-1818-05-2018
Board to consider Dividend
Granules India Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on May 24, 2018, inter alia, to consider and approve the Audited Financial Results for the fourth quarter and financial year ended March 31, 2018 and the recommendation of final dividend for the FY 2017-18, if any.Please be informed that Insider Trading Window of Granules India Limited is closed from 18th May 2018 to 26th May...18-05-2018
Granules India shares climb nearly 7% on USFDA nod for drug
The scrip advanced by 6.61% to end at Rs103.15 on BSE. Intra-day, it zoomed 10.18% to Rs106.60. On NSE, shares of the company surged 6.67% to close at Rs103.1517-05-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Granules Pharmaceuticals, Inc., a wholly owned subsidiary of Granules India Limited received US FDA approval for generic Methylergonovine tablets17-05-2018
Granules India gets EIR for Telangana facility
Granules India today said that the US health regulator has issued the Establishment Inspection Report (EIR) after completing the audit of its Telang16-05-2018
Receipt Of Establishment Inspection Report (EIR) US FDA -Reg.
Receipt of Establishment Inspection Report (EIR) US FDA -Reg.16-05-2018
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Krishna Prasad Chigurupati12-05-2018
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for IDBI Trusteeship Services Ltd11-05-2018